Study S002182

A Prospective, Non-interventional Study, Investigating Glycaemic Control and Treatment Patterns Associated With the Use of Once-daily Oral Semaglutide in Type 2 Diabetes Patients Who Intend to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait

ClinicalTrials.gov record

Registration

Registration: NCT05716724
Acronym: O-SEMA-Fast
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 288
Start: 2023-01-25
Primary completion: 2023-07-09
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1280-0404

Registered primary outcomes

Change in glycated haemoglobin (HbA1c) [From participant enrolment visit (0 to 8 weeks before Ramadan) to end of follow-up visit (0 to 8 weeks after Ramadan)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008168	O-SEMA-FAST: A Prospective, Non-interventional Study Investigating Oral Semaglutide Use in Adults with Type 2 Diabetes Mellitus During Ramadan. Hassanein M, Diabetes therapy : research, treatment and education of diabetes and related disorders	2025	Other trial	PMID 40016571 DOI	cites ClinicalTrials.gov:NCT05716724; registry reference DERIVED:40016571